GlassScriptPhysician profile
Amita Nair
NPI 1841363009
$382.69
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $383.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $78.02 | 2019 | |
| Radius Health, INC. | $73.16 | 2019 | |
| Amgen INC. | $42.74 | 2019 | |
| Scilex Pharmaceuticals INC. | $41.68 | 2019 | |
| Astellas Pharma US INC | $31.79 | 2019 | |
| Merck Sharp & Dohme LLC | $28.03 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $26.33 | 2019 | |
| Janssen Pharmaceuticals, INC | $16.95 | 2019 | |
| Amarin Pharma, INC. | $16.02 | 2019 | |
| Novo Nordisk INC | $15.26 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $12.71 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amita Nair listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.